Trial Profile
APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR Mutant NSCLC Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Osimertinib (Primary)
- Indications Adenocarcinoma; Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms APPLE
- 10 Mar 2024 According to an European Clinical Trials Database record, this trial has been completed in Slovenia.
- 28 Feb 2023 Results(n=103 ; of Arms B and C) assessing the feasibility of longitudinal plasma EGFR T790M monitoring for the best sequencing strategy of gefitinib and osimertinib published in the Annals of Oncology
- 13 Sep 2022 Results of arm B and arm C of this trial presented at the 47th European Society for Medical Oncology Congress